EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

Susan Manzi, Ian N Bruce, Eric F Morand iD, Richard Furie iD, Yoshiya Tanaka iD, Kenneth C Kalunian, Anca Askanase iD, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm und 1 weitere

Arthritis & Rheumatology · 2026-06 · 78 (6) · 1258-1267

DOI: 10.1002/art.70041 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, online erschienen am 17.02.2026. Verfasst von Susan Manzi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, Pennsylvania. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy.

Methods

Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 randomization). Only the primary endpoint (treatment difference in BILAG‐based Composite Lupus Assessment [BICLA] response at 52 weeks) was formally tested in a preplanned interim analysis; key secondary and other endpoints were tested in the full analysis.

Results

At the interim analysis (220 patients, anifrolumab: n = 109; placebo: n = 111), the primary endpoint was met (anifrolumab vs placebo: 59.4% vs 43.9%; BICLA response difference 15.5%, 95% confidence interval [95% CI] 2.3–28.6; P = 0.0211). The full analysis included 367 patients (anifrolumab: n = 184; placebo: n = 183). Versus placebo, more patients treated with anifrolumab attained a BICLA response while maintaining low/reduced oral glucocorticoid doses through week 52 (56.2% vs 34.0%; difference 22.3%, 95% CI 12.3–32.2; P < 0.0001), and the time to first sustained BICLA response was reduced (hazard ratio 2.2, 95% CI 1.5–3.2; P < 0.0001). Treatment differences in week 52 DORIS remission and Low Lupus Disease Activity State attainment rates favored anifrolumab over placebo (14.2%, 95% CI 5.6–22.8; P = 0.0012, and 14.1%, 95% CI 4.6–23.6; P = 0.0038). The frequencies of serious adverse events were 11.9% with anifrolumab and 10.4% with placebo; the frequencies of herpes zoster were 3.8% and 1.1%, respectively.

Conclusion

Consistent with the well‐established profile of intravenous anifrolumab, subcutaneous anifrolumab demonstrated significant, clinically meaningful treatment benefits when added to standard therapy, and an acceptable safety profile in patients with moderate to severe SLE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicAntibodies, Monoclonal, HumanizedHumansFemaleDouble-Blind MethodAdultMaleInjections, SubcutaneousMiddle AgedTreatment Outcome

Substanzen

Antibodies, Monoclonal, Humanizedanifrolumab

Autor:innen und Institutionen

  • Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, Pennsylvania.
  • Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom.
  • Centre for Public Health, Faculty of Medicine, Health, and Life Sciences, Queen's University Belfast, Belfast, United Kingdom.
  • Centre for Inflammatory Diseases, Monash University, Melbourne, Victoria, Australia.
  • Division of Rheumatology, Northwell, Great Neck, New York.
  • Department of Molecular Targeted Therapeutics, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.

ORCID-Profile: Eric F Morand, Richard Furie, Yoshiya Tanaka, Anca Askanase

Förderung

  • AstraZeneca

Zitieren

APA

Manzi, S., Bruce, I. N., Morand, E. F., Furie, R., Tanaka, Y., Kalunian, K. C., Askanase, A., Puzio, P., Khan, E., Wissmar, J., Song, M., Lindholm, C., & TULIP‐SC investigators (2026). Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study. Arthritis & Rheumatology, 78(6), 1258-1267. https://doi.org/10.1002/art.70041

Vancouver

Manzi S, Bruce IN, Morand EF, Furie R, Tanaka Y, Kalunian KC, et al. Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study. Arthritis & Rheumatology. 2026;78(6):1258-1267. doi:10.1002/art.70041

BibTeX
@article{Manzi2026,
  author = {Manzi, Susan and Bruce, Ian N and Morand, Eric F and Furie, Richard and Tanaka, Yoshiya and Kalunian, Kenneth C and Askanase, Anca and Puzio, Patricia and Khan, Emon and Wissmar, Jenny and Song, Michael and Lindholm, Catharina and TULIP‐SC investigators, TULIP‐SC investigators},
  title = {Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  volume = {78},
  number = {6},
  pages = {1258--1267},
  doi = {10.1002/art.70041}
}
Kostenlos starten →